NASDAQ:CBPO - China Biologic Products Stock Price, News & Analysis

-0.84 (-0.85 %)
(As of 08/25/2019 08:24 AM ET)
Today's Range
Now: $97.86
50-Day Range
MA: $95.61
52-Week Range
Now: $97.86
Volume72,441 shs
Average Volume130,774 shs
Market Capitalization$3.85 billion
P/E Ratio24.32
Dividend YieldN/A
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CBPO



Sales & Book Value

Annual Sales$466.88 million
Cash Flow$5.0469 per share
Book Value$46.40 per share


Net Income$128.06 million


Market Cap$3.85 billion
Next Earnings Date11/7/2019 (Estimated)

Receive CBPO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter.

China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions

What is China Biologic Products' stock symbol?

China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."

How were China Biologic Products' earnings last quarter?

China Biologic Products Holdings Inc (NASDAQ:CBPO) announced its quarterly earnings data on Monday, August, 5th. The biopharmaceutical company reported $1.24 EPS for the quarter, topping the Zacks' consensus estimate of $1.03 by $0.21. The biopharmaceutical company earned $135.70 million during the quarter. China Biologic Products had a return on equity of 8.56% and a net margin of 29.46%. The company's revenue was up 12.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.17 earnings per share. View China Biologic Products' Earnings History.

When is China Biologic Products' next earnings date?

China Biologic Products is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for China Biologic Products.

What guidance has China Biologic Products issued on next quarter's earnings?

China Biologic Products updated its FY19 earnings guidance on Monday, August, 5th. The company provided earnings per share guidance of $4.18-4.26 for the period, compared to the Thomson Reuters consensus estimate of $4.07.

What price target have analysts set for CBPO?

3 analysts have issued 12-month price targets for China Biologic Products' stock. Their forecasts range from $62.00 to $88.00. On average, they expect China Biologic Products' share price to reach $78.00 in the next year. This suggests that the stock has a possible downside of 20.3%. View Analyst Price Targets for China Biologic Products.

What is the consensus analysts' recommendation for China Biologic Products?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products.

Has China Biologic Products been receiving favorable news coverage?

News headlines about CBPO stock have trended positive on Sunday, InfoTrie reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. China Biologic Products earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for China Biologic Products.

Are investors shorting China Biologic Products?

China Biologic Products saw a decline in short interest in the month of July. As of July 15th, there was short interest totalling 938,200 shares, a decline of 10.8% from the June 15th total of 1,052,200 shares. Based on an average daily volume of 178,500 shares, the days-to-cover ratio is presently 5.3 days. Currently, 4.3% of the shares of the stock are sold short. View China Biologic Products' Current Options Chain.

Who are some of China Biologic Products' key competitors?

What other stocks do shareholders of China Biologic Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), Sarepta Therapeutics (SRPT), The Carlyle Group (CG), Gilead Sciences (GILD), GSI Technology (GSIT), ACADIA Pharmaceuticals (ACAD), Amgen (AMGN), Biogen (BIIB), RYB Education (RYB) and NVIDIA (NVDA).

Who are China Biologic Products' key executives?

China Biologic Products' management team includes the folowing people:
  • Mr. Ming Yang, Chief Financial Officer (Age 47)
  • Mr. Ming Yin, Sr. VP (Age 41)
  • Ms. Zhijing Liu, Corp. VP (Age 65)
  • Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 54)
  • Dr. Bing Li Ph.D., CEO & Director (Age 51)

Who are China Biologic Products' major shareholders?

China Biologic Products' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include York Capital Management Global Advisors LLC (2.87%), Vanguard Group Inc. (2.41%), Bank of America Corp DE (2.10%), BlackRock Inc. (1.00%), Maso Capital Partners Ltd (0.38%) and Wasatch Advisors Inc. (0.30%). View Institutional Ownership Trends for China Biologic Products.

Which institutional investors are selling China Biologic Products stock?

CBPO stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, UBS Asset Management Americas Inc., Wasatch Advisors Inc., BlackRock Inc., Renaissance Technologies LLC, Dalton Investments LLC, Parametric Portfolio Associates LLC and Maso Capital Partners Ltd. View Insider Buying and Selling for China Biologic Products.

Which institutional investors are buying China Biologic Products stock?

CBPO stock was bought by a variety of institutional investors in the last quarter, including York Capital Management Global Advisors LLC, Canada Pension Plan Investment Board, Point72 Asset Management L.P., Nikko Asset Management Americas Inc., Vanguard Group Inc., Jane Street Group LLC, Paradice Investment Management LLC and SG Americas Securities LLC. View Insider Buying and Selling for China Biologic Products.

How do I buy shares of China Biologic Products?

Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is China Biologic Products' stock price today?

One share of CBPO stock can currently be purchased for approximately $97.86.

How big of a company is China Biologic Products?

China Biologic Products has a market capitalization of $3.85 billion and generates $466.88 million in revenue each year. The biopharmaceutical company earns $128.06 million in net income (profit) each year or $4.02 on an earnings per share basis. China Biologic Products employs 2,187 workers across the globe.View Additional Information About China Biologic Products.

What is China Biologic Products' official website?

The official website for China Biologic Products is

How can I contact China Biologic Products?

China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]

MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  400 (Vote Underperform)
Total Votes:  712
MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel